Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioma 3Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Diffuse Intrinsic Pontine Glioma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Obesity 1Neoplasm Metastasis 1Meningioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease 1Carcinosarcoma 1

Interventions

Paclitaxel 69Bevacizumab 62Carboplatin 53pembrolizumab 46olaparib 32Specimen Handling 27Gemcitabine 27Cyclophosphamide 26Magnetic Resonance Spectroscopy 24liposomal doxorubicin 22Cisplatin 21niraparib 20Taxes 18Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 12Fulvestrant 12Disulfides 12Oxaliplatin 10mirvetuximab soravtansine 9durvalumab 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9Blood Specimen Collection 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × TIC10 compound × 1 year × Clear all
NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
62 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡